pharmaphorum

JANUARY 3, 2023

Ben Hargreaves examines why there is no easy answer to the question of when palliative care is the right option for patients. However, the authors concluded that the emergence of such treatments had led to “the tendency to use immunotherapy in EOL (end-of-life) settings where less aggressive approaches may be preferable.”

Research 105

Research Scientist Medicine Development 105

pharmaphorum

NOVEMBER 28, 2022

With COP27 concluding in November, Ben Hargreaves takes a look at what efforts pharma companies are making to limit their environmental impact. The authors outline that the process “is no different from a business’s commercial agenda. The past eight years are set to be the eight warmest on record.

Pharma Companies 98

Pharma Companies Production Marketing 98

pharmaphorum

DECEMBER 16, 2022

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Further, with a pandemic treaty in development, there are reasons to believe that many countries and the WHO want to see a more equitable distribution of medical products for future pandemics.

Vaccination 96

Vaccination Vaccine Production Licensing 96

pharmaphorum

JUNE 28, 2022

In the first of a three part series, Ben Hargreaves looks at what the odds are of another pandemic arising in our lifetimes and what can be done to lower the risk of this happening again. The authors suggest that even a 1% reduction in risk of viral zoonotic disease emergence would make any efforts in this direction cost-effective.

Vaccination 52

Vaccination Vaccine Development Research 52

pharmaphorum

JUNE 2, 2022

However, Ben Hargreaves finds that the blockbuster success that certain treatments are achieving is beginning to raise questions over whether healthcare systems can afford this in the long-term.

Drugs 52

Drugs Sales Marketing Development 52

pharmaphorum

JANUARY 10, 2022

Ben Hargreaves takes a look at how the space is currently progressing and in what direction it could be heading in future. The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease.

RNA 110

RNA Vaccination Vaccine Pharma Companies 110

pharmaphorum

NOVEMBER 16, 2022

However, alongside this progress, Ben Hargreaves finds that there is also a conundrum over how to price these therapies. The authors write that the majority of the world is excluded from the benefits of modern medicine, and called for greater effort to cater research and financing for low- to middle-income countries.

Gene Therapy 131

Gene Therapy Gene Marketing Development 131